跳至主要内容
临床试验/NL-OMON51806
NL-OMON51806尚未招募3 期

Validation of ICG-99mTc-nanoscan as hybrid tracer for sentinel node biopsy - NANOSCA

Antoni van Leeuwenhoek Ziekenhuis0 个研究点目标入组 29 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
尚未招募
发起方
入组人数
29

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • * Patient who will undergo a sentinel node procedure in routine care.
  • * Patients > 18 years;
  • * Patients presenting with a primary cutaneous melanoma of head/neck, upper
  • part of the trunk, and extremities;
  • * Patients presenting with a primary oral cavity malignancyT1-2N0;
  • * Patients with primary penile cancer;
  • * Patients with clinical N0 stage;
  • * Patients scheduled for a sentinel node biopsy prior to (re-)excision of the
  • primary lesion;
  • * Patients in which ICG-99mTc-nanoscan would be used in routine care or a
  • research setting

排除标准

  • * Patients with known allergy to patent blue dye;
  • * Patients who are pregnant or breast-feeding mothers;
  • * History of hypersensitivity reactions to products containing human serum
  • * History of iodine allergy
  • * Hyperthyroid or thyroidal adenoma
  • * Kidney insufficiency
  • * Incapacity or unwillingness of participant to give written informed consent;

研究者

发起方
Antoni van Leeuwenhoek Ziekenhuis

相似试验